Merit Medical Systems, Inc. provided earnings guidance for the full year ending December 31, 2022. Based upon information currently available to Merit's management, for the year ending December 31, 2022, absent material acquisitions, non-recurring transactions or other factors beyond Merit's current expectations, Merit now expects the following: Net revenue in the range of $1.123 billion to $1.135 billion, representing an increase of approximately 5% to 6% year-over-year, as compared to net revenue of $1.075 billion for the twelve months ended December 31, 2021. The fiscal year 2022 revenue guidance range assumes: Net revenue from Merit's cardiovascular segment of between $1.093 billion and $1.102 billion, representing an increase of approximately 5% to 6% year-over-year as compared to net revenue of $1.043 billion for the twelve months ended December 31, 2021.

Net revenue from Merit's endoscopy segment of between $30.0 million and $34.0 million, representing a range of a 5% decline to an 8% increase year-over-year as compared to net revenue of $31.5 million for the twelve months ended December 31, 2021. GAAP net income in the range of $62.4 million to $68.3 million, or $1.08 to $1.18 per diluted share, compared to GAAP net income of $48.5 million, or $0.84 per diluted share, for the twelve months ended December 31, 2021.